[Treatment of non-small cell bronchial cancer with high-dosage cisplatin and vindesine. Results of a prospective study].

Thirty-seven patients with advanced, histologically confirmed non-small-cell lung cancer received combination chemotherapy with high-dose (120 mg/m2, day 1 and 29, thereafter every 6 weeks) cisplatin and vindesine (3 mg/m2, day 1, 8, 15, 22, and 29, thereafter every two weeks). All patients had measurable disease and had not previously received chemotherapy. 20 out of 37 patients responded to therapy. Two patients with adenocarcinoma, and one patient with squamous carcinoma of the lung experienced complete remission, 11 out of 37 patients partial remission, three patients a minor response, while in three patients the tumour neither remitted nor progressed. Despite chemotherapy cancer progressed in 17 out of 37 patients. Under supportive care including prehydratation, diuresis, administration of high-dose metoclopramide this aggressive chemotherapy was well tolerated. The response rate was similar to that of other chemotherapeutic regimens. The remission duration (9.5 months) and the survival time (16.5 months) are, however, somewhat better.